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STI diagnoses, sexualised drug use and associations with PrEP use among 
men who have sex with men in the UK 
Abstract 
Previous research has focused on acceptability of PrEP use, but few community-based studies 
have been conducted regarding actual use, and PrEP use in the context of sexualised drug use 
remains understudied. A national online cross-sectional study recruited MSM via social 
media (April-June 2018). Multivariable logistic regression was used to investigate factors 
associated with PrEP use. Bivariate analyses compared engaging in condomless anal 
intercourse (CAI) under the influence of specific drugs and recent STI diagnoses (past 12 
months) between MSM taking PrEP and those not. Overall, 6% (99/1,581) MSM reported 
current PrEP use. Factors associated with PrEP use were increasing age, recent GUM 
attendance (95% vs. 45%, aOR=6.25, 95%CI 2.05, 19.03), an HIV test in the past three 
months (89% vs. 23%, aOR=14.22, 95%CI 6.76, 29.90), and recent engagement in chemsex 
(21% vs. 4%, aOR=3.56, 95%CI 1.78, 7.11). MSM taking PrEP were more likely to have had 
an STI diagnosis (42% vs. 8%), most commonly chlamydia (26% vs. 3%) and gonorrhoea 
(25% vs. 4%). Considering the elevated levels of self-reported STI diagnoses among those on 
PrEP, there was a high level of engagement with sexual health services, which may help 
reduce onward STI transmission.  
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Introduction 
Since 2015, there has been a sharp decline in new HIV diagnoses among men who 
have sex with men (MSM) in the UK, particularly among MSM in London.1 Whilst the 
decline has been attributed mostly to an increase in HIV testing among this population, as 
well as the use of antiretroviral therapy for treatment as prevention,2 the role that pre-
exposure prophylaxis (PrEP) could play in ending the HIV epidemic in the UK should not be 
underestimated.3 PrEP is the use of antiretroviral medication, either taken daily or around a 
specific sexual event, to reduce a person’s likelihood of acquiring HIV.4 Recent PrEP 
guidelines published by the British HIV Association (BHIVA) suggest PrEP be prescribed to 
MSM at risk of HIV, with testing for HIV and bacterial STIs conducted every three months.5 
NHS England began the PrEP IMPACT trial in October 2017, providing PrEP to 10,000 at-
risk participants,6 although MSM unable to secure a place on the trial could self-source PrEP 
online through websites designed to source generic versions of tenofovir/emtricitabine, such 
as IWantPrEPNow.com. Although the number of places on the trial have now been extended 
to 26,000 (www,prepimpacttrial.org.uk), in Scotland, PrEP provision was commissioned by 
the NHS in 2017, creating what some have described as a ‘postcode lottery’ for access to 
PrEP within the UK.7  
The PROUD study among MSM in England found that daily PrEP use was 86% 
effective at reducing HIV acquisition, and although STI rates were higher in the immediate 
vs. deferred group, this did not reach statistical significance.8 Despite this, concerns over 
greater sexual risk taking among PrEP users has risen,9,10 which may have been intensified by 
the increase of chlamydia, gonorrhoea and syphilis diagnoses among MSM in the UK over 
the past decade, with MSM accounting for 75% of syphilis diagnoses in 2018.11 The threat of 
antimicrobial resistant gonorrhoea among MSM in England and Wales, as well as the first 
international case of extensively drug resistant gonorrhoea reported in South East Asia further 
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elevates this concern.12 However, it has been argued that provision of PrEP could help reduce 
incidence of STIs among MSM, as contact with sexual health services for PrEP will also 
encourage regular STI testing and treatment.13  
It has been suggested that the increase in STI incidence seen among MSM could be 
due to an increase in condomless anal intercourse, group sex facilitated by geospatial apps, 
and chemsex.14 In the UK, chemsex is a particular form of sexualised drug use (SDU), 
associated with taking crystal methamphetamine, γ-hydroxybutyrate/γ-butyrolactone 
(GHB/GBL), mephedrone, and/or ketamine immediately before or during sex to facilitate the 
experience.15 Chemsex has been associated with condomless anal intercourse and STI 
incidence.16-18 Additionally, other substances used to facilitate the sexual experience such as 
poppers and erectile dysfunction drugs have also been associated with condomless sex.19 In 
Amsterdam, a higher proportion of MSM engaging in chemsex were taking pre-exposure 
prophylaxis (PrEP) compared to MSM not engaging in chemsex.20 Chemsex has also been 
associated with accessing post-exposure prophylaxis (PEP) at a sexual health clinic in 
Brighton, UK.21  
Among MSM using geospatial apps in London, over half of participants were willing 
or very willing to use PrEP, and recent STI diagnosis was associated with willingness.22 
Additionally, those aged 18 to 24 were more likely to agree that they would not take PrEP if 
it were to become available as they would forget to take it every day.22 In Leicester, UK, 
PrEP acceptability was associated with greater perceived HIV risk, recent STI acquisition, 
greater sexual risk and frequency of HIV testing.23 In a global systematic review of PrEP 
acceptability among MSM, those who were younger, better educated, wealthier, and aware of 
PrEP were more likely to accept PrEP, whereas concerns about side effects, adherence and 
stigma were identified as barriers.24  
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Whilst research has been conducted on the acceptability and intention of taking PrEP 
among MSM, research has rarely focused on factors associated with actual PrEP use. 
Identifying factors associated with PrEP use will also inform understanding of the barriers to 
care for those who may need it. The aim of this research is to understand factors associated 
with self-reported PrEP use among MSM across the UK, and to investigate the sexual health 
behaviours of those currently taking PrEP, particularly sexualised drug use.  
Methods 
Participants 
The LGBT Sex and Lifestyles Survey was a national cross-sectional study aimed at 
LGBT people over the age of 18, living in the UK. A convenience sample was obtained using 
sponsored Facebook advertising and through LGBT community organisations’ social media 
accounts between April-June 2018. Potential participants were shown the adverts if they 
engaged in any LGBT associated content on Facebook. Four adverts aimed at MSM, WSW, 
trans people and LGBT generally were used to recruit participants. Participants were invited 
to take part if they had ever had sex with someone of the same gender or identified as trans. 
Potential participants were then directed to the online survey and asked two screening 
questions, ensuring that the participants were aged eighteen or over and currently lived in the 
UK. To aid recruitment participants had the option to enter a prize draw for a £50 or one of 
two £25 Amazon vouchers. This analysis focuses on those respondents who were MSM. 
Ethical approval for this study was obtained from the Liverpool John Moores University 
Research Ethics Committee (approval reference:18/PHI/011).  
Measures 
 The survey was divided into three sections: demographics (gender, age, ethnicity, 
country of birth, employment, education level, sexuality); sexual health and drug use, and 
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psychological wellbeing. Participants were grouped as MSM if they identified as male and 
reported having sex with men. An adapted two-stage gender monitoring question was used,25 
which first asked which of the following best describes how you think of yourself: male 
(including trans man); female (including trans woman); non-binary; in another way, please 
specify; and prefer not to say. This was followed by asking if their gender identity is the same 
as the gender they were assigned at birth. 
Sexual health and drug use questions were adapted from cross-sectional surveys on 
similar topics.26,27 Participants were asked if they had attended a GUM/sexual health clinic in 
the past 12 months, and if they had been diagnosed with chlamydia, gonorrhoea, genital 
warts, herpes, LGV, syphillis, shigella, or Hepatitis C in the past 12 months. Participants 
were asked their HIV status and participants who were not living with HIV were asked when 
did they last have an HIV test (in the last 3 months, 3-12 months, 1-5 years, greater than 5 
years, never). Those who were not living with HIV were also asked if they are currently 
taking PrEP.  
Aligned with previous research, questions about drug use and SDU were asked with 
regards to specific drugs.28 Participants were first asked if they had taken any of the 14 listed 
drugs (including alcohol) in the past 12 months. Participants were then asked if they had been 
under the influence of alcohol or cannabis in the past 12 months, and if they had taken 
amphetamine, cocaine, crack cocaine, ecstasy, heroin, GHB/GBL, ketamine, mephedrone, 
methamphetamine, Viagra or other erectile dysfunction drug (EDD), poppers, or another 
unspecified drug just before or during sex in the past 12 months. This was followed by a 
question asking whether the participant engaged in condomless anal intercourse (CAI) the 
last time they had taken specific drug for sex. The chemsex group was defined as having 
taken GHB/GBL, ketamine, mephedrone and/or meth-amphetamine just before or during sex. 
All other drugs besides alcohol were grouped as other sexualised drug use.  
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Sexual satisfaction was measured using an adapted version of the New Sexual 
Satisfaction Scale.29 The 12 items were measured on a 5-point scale (“Not at all satisfied”, “A 
little satisfied”, “Moderately satisfied”, “Very satisfied”, “Extremely satisfied”). Cronbach’s 
Alpha for this measure was 0.92. The questions were adapted by replacing “my partner” to 
“the person I have sex with” to emphasise sexual satisfaction in general, and not just specific 
to one partner. 
Statistical analyses 
All analyses were conducted using SPSS 25 (IBM Corp., Armonk, NY). Forward 
stepwise multivariable logistic regression analyses were used to explore factors associated 
with current PrEP use among MSM (entry p<0.05, removal p>0.10). Any factor significant at 
the bivariate level (p<0.10) was included in the multivariable analysis. Where participants 
had not answered a specific question (not reported), these data were not included in the 
bivariate and multivariable analyses. Descriptive chi-square analyses were used to compare 
engagement in CAI among those engaging in anal intercourse under the influence of specific 
substances between MSM who reported being on PrEP and those who did not, as well as 
comparing STI/BBV diagnoses in the past 12 months between MSM who reported being on 
PrEP and those who did not. Fisher’s Exact test was used where cell values were less than or 
equal to five.  
Results 
Of the 4,690 surveys started, 3,676 completed the questionnaire (completion rate 
78%). There were 1,663 (45%) participants who identified as MSM, and MSM who 
completed the questionnaire were more likely to be university educated (53% vs. 61%, 
p<0.05), but did not differ on any other demographic variables from those MSM who started 
the survey but did not complete where data were available (n=344). The median time taken to 
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complete the survey was 12 minutes. Seventy-five (5%) were MSM living with HIV, and 
seven did not answer the PrEP question, so a total of 1,581 MSM (95%) were included in the 
analysis. Of those included, 85% (n=1,349) identified as gay/homosexual, had a median age 
of 28 (IQR=22-34, range 18-76), 96% (n=1,510) were of white ethnicity and 6% (n=99) 
reported currently taking PrEP. There were 102 (6.5%) trans men who identified as MSM 
included in the analysis, one of which reported currently taking PrEP. MSM living in 
Scotland (n=18/169, 11%) were significantly more likely to report current PrEP use 
compared to MSM outside of Scotland (n=81/1407, 6%)(p<0.05).  
Table 1 displays the bivariate and multivariable analysis for factors associated with 
taking PrEP. In the multivariable analysis, taking PrEP was associated with being aged 25 
and over, having attended a GUM clinic in the past 12 months, having an HIV test in the past 
3 months, and having engaged in chemsex in the past 12 months. Having a highest 
educational achievement at 16 was associated with a reduced likelihood of current PrEP use. 
MSM currently taking PrEP were more likely to report engaging in any anal intercourse than 
those not taking PrEP (100%, n=99/99 vs. 84%, n=1240/1482, p<0.001; median=15, IQR=6-
30 vs median=1, IQR=1-4) and more likely to report engaging in condomless anal intercourse 
(96% n=94/98 vs. 62% n=913/1480, p<0.001; median=8, IQR=3-19.5 vs median=1, IQR=0-
1).The multivariable analysis was repeated for MSM who had engaged in CAI only, and 
found the same factors were associated with PrEP use among those who had engaged in CAI. 
The questions about alcohol and drug use were answered by 1,572 MSM, 6% (n=99) 
of which were currently taking PrEP (n=1,473 not currently taking PrEP). To investigate 
substance use in a sexual context in relation to PrEP use, drug use, sexualised drug use, and 
event-level condom use under the influence of specific drugs by current PrEP use are given in 
Table 2. Participants taking PrEP were more likely to have taken cocaine, crystal meth, 
esctacy, GHB/GBL, mephedrone, poppers and EDDs, and were more likely to report having 
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had sex under the influence of alcohol and cannabis, and more likely to have taken cocaine, 
GHB/GBL, mephedrone and poppers immediately before or during sex. Among those 
participants who had engaged in anal intercourse under the influence of alcohol or cannabis, 
those who engaged in CAI were more likely to be taking PrEP. Additionally, among those 
who had taken poppers or EDDs immediately before or during anal intercourse, those who 
engaged in CAI were also statistically more likely to be taking PrEP. 
Figure 1 displays self-reported STI/BBV diagnoses in the past 12 months between 
MSM who are currently taking PrEP and those who are not. MSM currently taking PrEP 
were more likely to have been diagnosed with any STI/BBV in the past 12 months, 
particularly chlamydia, gonnorhoea, herpes, LGV, and syphillis. No participants in this 
analysis reported having been diagnosed with shigella in the past 12 months. Of those 
diagnosed with an STI/BBV, being diagnosed with two or more STI/BBV in the past 12 
months was more common among MSM on PrEP (n=18/41, 44%) than MSM not on PrEP 
(n=26/116, 22%)(p<0.01). The most common combination of diagnoses was chlamydia and 
gonorrhoea (n=27/44, 61%).
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Table 1. Bivariate and multivariable analyses of factors associated with current PrEP use among all MSM and those MSM who have engaged in recent CAI. 
 Current PrEP use among all participants Bivariate Multivariable† 
Current PrEP use among those who have 
engaged in CAI in the past 12 months Bivariate Multivariable†† 
 No (n=1,485)  Yes (n=99)  OR (95% CI) aOR (95% CI) No (n=913) Yes (n=94) OR (95% CI) aOR (95% CI) 
 
n or 
mean 
% or 
SD 
n or 
mean 
% or 
SD 
Row 
%   
n or 
mean 
% or 
SD 
n or 
mean 
% or 
SD 
Row 
% 
  
Sexuality               
Homosexual 1258 85% 91 92% 7% ref.  814 89% 88 94% 10% ref.  
Bisexual 147 10% 3 3% 2% 0.28 (0.09, 0.90)  68 7% 1 1% 1% 0.14 (0.02, 0.99)  
Heterosexual 1 0.1% 0 0% 0% -  0 0% 0 0%  -  
Queer 45 3% 4 4% 8% 0.70 (0.43, 3.49)  17 2% 4 4% 19% 2.18 (0.72, 6.61)  
Not reported* 34 2% 1 1% 3%   14 2% 1 1% 7%   
Age group               
18-24 523 35% 11 11% 2% ref. ref. 315 35% 9 10% 3% ref. ref. 
25-34 571 38% 49 49% 8% 4.08 (2.10, 7.93) 4.52 (2.11, 9.68) 375 41% 47 50% 11% 4.39 (2.12, 9.09) 5.31 (2.30, 12.26) 
35-49 298 20% 32 32% 10% 5.11 (2.54, 10.28) 7.51 (3.35, 16.87) 188 21% 31 33% 14% 5.77 (2.69, 12.39) 9.95 (4.07, 24.28) 
50+ 90 6% 7 7% 7% 3.70 (1.40, 9.79) 8.28 (2.59, 26.43) 32 4% 7 7% 18% 7.66 (2.67, 21.94) 23.93 (5.71, 100.22) 
Not reported* 3 0.2% 0 0% 0%   3 0.3% 0 0% 0%   
Ethnicity               
White 1417 95% 93 94% 6% ref.  875 96% 88 94% 9% ref.  
Person of colour 65 4% 6 6% 8% 1.41 (0.59, 3.33)  36 4% 6 6% 14% 1.66 (0.68, 4.04)  
Not reported* 3 0.2% 0 0% 0%   2 0.2% 0 0% 0%   
Country of Birth               
UK 1291 87% 83 84% 6% ref.  798 87% 78 83% 9% ref.  
Not UK 161 11% 14 14% 8% 1.35 (0.75, 2.44)  99 11% 14 15% 12% 1.45 (0.79, 2.65)  
Not reported* 33 2% 2 2% 7%   16 2% 2 2% 11%   
Education               
University or higher 858 58% 71 72% 8% ref. ref. 532 58% 69 73% 11% ref. ref. 
Qualifications at 18 434 29% 24 24% 5% 0.67 (0.42, 1.08) 1.12 (0.62, 2.01) 264 29% 21 22% 7% 0.61 (0.37, 1.02) 0.87 (0.46, 1.68) 
Qualifications at 16 
or lower  
153 10% 3 3% 2% 0.24 (0.07, 0.76) 0.13 (0.03, 0.58) 91 10% 3 3% 3% 0.25 (0.08, 0.83) 0.10 (0.02, 0.52) 
Not reported* 40 3% 1 1% 3%   26 3% 1 1% 4%   
Work Status               
Full time 927 62% 70 71% 7% ref.  608 67% 66 70% 10% ref.  
Part time 106 7% 4 4% 4% 0.50 (0.18, 1.40)  64 7% 4 4% 6% 0.58 (0.20, 1.63)  
Student 254 17% 10 10% 4% 0.52 (0.27, 1.03)  135 15% 9 10% 6% 0.61 (0.30, 1.26)  
Unemployed 56 4% 2 2% 3% 0.47 (0.11, 1.98)  31 3% 2 2% 6% 0.59 (0.14, 2.54)  
Other 132 9% 13 13% 9% 1.30 (0.70, 2.42)  68 7% 13 14% 16% 1.76 (0.92, 3.36)  
Not reported* 10 0.7% 0 0% 0%   7 0.8% 0 0% 0%   
Relationship status               
Living with partner 528 36% 26 26% 5% ref.  385 42% 25 27% 6% ref.  
Relationship not 
living with partner 
304 20% 9 9% 3% 0.60 (0.28, 1.30)  193 21% 9 10% 4% 
0.72 (0.33, 1.57)  
Relationship with 
multiple 
29 2% 5 5% 15% 3.50 (1.25, 9.78)  18 2% 5 5% 22% 
4.28 (1.47, 12.47)  
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Single 621 42% 59 60% 9% 1.93 (1.20, 3.10)  316 35% 55 59% 15% 2.68 (1.63, 4.40)  
Not reported* 3 0.2% 0 0% 0%   1 0% 0 0% 0%   
London               
Outside London 1253 84% 71 72% 5% ref.  761 83% 66 70% 8% ref.  
London 224 15% 28 28% 11% 2.21 (1.39, 3.49)  148 16% 28 30% 16% 2.18 (1.36, 3.51)  
Not reported* 8 0.5% 0 0% 0%   4 0.4% 0 0% 0%   
Attended GUM               
No 794 53% 5 5% 1% ref. ref. 434 48% 2 2% 0% ref. ref. 
Yes 660 44% 94 95% 12% 22.62 (9.15, 55.93) 6.28 (2.06, 19.19) 468 51% 92 98% 16% 42.66 (10.45, 174.20) 9.40 (2.15, 41.18) 
Not sure 19 1% 0 0% 0% - - 7 1% 0 0% 0% -  
Not reported* 12 0.8% 0 0% 0%   4 0.4% 0 0% 0%   
HIV testing               
Never 287 19% 2 2% 1% ref. ref. 544 60% 8 9% 1% ref. ref. 
In the last 3 months 348 23% 88 89% 20% 23.85 (11.88, 47.90) 14.13 (6.72, 29.71) 251 27% 86 91% 26% 23.30 (11.12, 48.82) 15.29 (6.92, 33.80) 
Over 3 months ago 847 57% 9 9% 1% 0.66 (0.14, 3.06) 3.07 (0.55, 17.13) 118 13% 0 0% 0% -  
Not reported* 3 0.2% 0 0% 0%   0 0% 0 0%    
Chemsex past 12 
months 
       
 
    
  
No 1415 95% 78 79% 5% ref. ref. 856 94% 73 78% 58% ref. ref. 
Yes 58 4% 21 21% 27% 6.57 (3.79, 11.37) 3.55 (1.78, 7.09) 52 6% 21 22% 81% 4.74 (2.70, 8.29) 3.19 (1.53, 6.66) 
Not reported 12 0.8% 0 0% 0%   5 0.5% 0 0% 0%   
Other sexualised 
drug use 
              
No 931 63% 29 29% 3% ref.  509 56% 25 27% 5% ref.  
Yes 542 36% 70 71% 11% 4.15 (2.66, 6.47)  399 44% 69 73% 15% 3.52 (2.19, 5.67)  
Not reported* 12 0.8% 0 0% 0%   5 0.5% 0 0% 0%   
Sex under the 
influence of alcohol 
              
No 513 35% 19 19% 4% ref.  249 27% 19 20% 7% ref.  
Yes 960 65% 80 81% 8% 2.25 (1.35, 3.75)  659 72% 75 80% 10% 1.49 (0.88, 2.51)  
Not reported* 12 0.8% 0 0% 0%   5 0.5% 0 0% 0%   
Sexual satisfaction 41.2 9.1 43.9 8.6  1.04 (1.01, 1.06)  42.3 8.36 44.1 8.57  1.03 (1.00, 1.06)  
† Factors included in the multivariable analysis (N=XXX) : Sexuality, Age group, Education, Work Status, Relationship Status, London, Attended GUM, HIV testing, Chemsex past 12 months, Other sexualised 
drug use, sex under the influence of alcohol, Sexual satisfaction. 
†† Factors included in the multivariable analysis (N=XXX): Sexuality, Age group, Education, Work Status, Relationship Status, London, Attended GUM, HIV testing, Chemsex past 12 months, Other sexualised 
drug use, Sexual satisfaction. 
* Excluded from analyses. 
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Table 2. Drug use, sexualised drug use and event-level condom use under the influence of drugs by PrEP use 
among MSM. 
 Current PrEP use  
 No (n=1,473) Yes (n=99)  
 n %  n %  p value 
Alcohol      
Taken 1388 94% 91 92% 0.346 
Had sex under the influence of 960 69% 80 88% <0.001 
  Of those who had anal intercourse      
    Condom used 230 29% 8 11% 
0.001 
    CAI 577 71% 68 89% 
Cannabis      
Taken 439 30% 29 29% 0.914 
Had sex under the influence of 191 44% 19 67% 0.021 
  Of those who had anal intercourse      
    Condom used 52 33% 1 6% 
0.042 
    CAI 106 67% 15 94% 
Cocaine      
Taken 301 20% 31 31% 0.010 
Taken immediately before or during sex 122 41% 20 65% 0.010 
  Of those that had anal intercourse      
    Condom used 23 21% 2 11% 
0.528 
    CAI 88 79% 17 89% 
Crystal meth      
Taken 18 1% 13 13% <0.001 
Taken immediately before or during sex 13 72% 11 85% 0.667 
  Of those that had anal intercourse      
    Condom used 1 8% 0 0% 
1.00 
    CAI 11 92% 11 100% 
Ecstasy      
Taken 176 12% 21 21% 0.007 
Taken immediately before or during sex 46 26% 9 43% 0.106 
  Of those that had anal intercourse      
    Condom used 8 21% 2 22% 
1.00 
    CAI 30 79% 7 78% 
GHB/GBL      
Taken 37 3% 17 17% <0.001 
Taken immediately before or during sex 25 68% 16 94% 0.043 
  Of those that had anal intercourse      
    Condom used 6 26% 0 0% 
0.064 
    CAI 17 74% 16 100% 
Mephedrone      
Taken 55 4% 17 17% <0.001 
Taken immediately before or during sex 29 53% 14 82% 0.046 
  Of those that had anal intercourse      
    Condom used 4 15% 0 0% 
0.278 
    CAI 22 85% 14 100% 
Poppers      
Taken 460 31% 61 62% <0.001 
Taken immediately before or during sex 366 80% 56 92% 0.022 
  Of those that had anal intercourse      
    Condom used 109 33% 4 7% 
<0.001 
    CAI 226 67% 51 93% 
EDD      
Taken 161 11% 32 32% <0.001 
Taken immediately before or during sex 147 91% 31 97% 0.473 
  Of those that had anal intercourse      
    Condom used 43 31% 0 0% 
<0.001 
    CAI 95 69% 31 100% 
Taken percentage is of total taking/not taking PrEP. Had sex under the influence of/taken immediately before or during sex percentage is of 
those who reported taking the substance. Condom use/CAI percentage is of those who reported sex under the influence or taken immediately 
before or during sex, excluding those that did not report anal intercourse. 
Fisher’s Exact test used where cells <=5 
CAI – Condomless anal intercourse 
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Figure 1. STI/BBV diagnoses in the past 12 months and PrEP use among MSM. 
Fisher’s Exact test used where cells <=5 
 
Discussion 
The aim of this study was to investigate the sexual health behaviours of MSM taking 
PrEP. It was found that 89% of MSM on PrEP in this sample were adhering to BHIVA 
guidelines by having attended for an HIV test in the past 3 months, and this rose to 98% 
among those that had engaged in CAI.5 MSM in Scotland were more likely to report taking 
PrEP, potentially reflecting the inequality of access to PrEP within the UK.7 PrEP was 
associated with higher reported STI diagnoses, and whilst the differences may appear striking 
at first, it is important to note that unlike the PROUD study, our sample of MSM on PrEP 
was not compared to a sample with similar sexual risk taking, due to the small number of STI 
diagnoses reported.8 Therefore, it may be that our sample of MSM on PrEP are protecting 
themselves against HIV acquisition and would be at increased risk of STI diagnosis 
regardless of their PrEP use. Higher levels of STIs have been observed among MSM taking 
PrEP internationally,10 and the higher levels of self-reported STI diagnoses could be due to 
increased engagement with care, as MSM on PrEP were more likely to have attended a GUM 
clinic in the past 12 months compared to those who were not, and guidelines state MSM on 
PrEP should attend sexual health care every three months.5 This could be seen as a benefit of 
PrEP, as engaging in services more frequently may help prevent onward transmission of 
STIs.13 Sexual satisfaction was associated with PrEP use in the bivariate analyses, but not in 
the multivariable, possibly due to a relationship between this and sexualised drug use.30 This 
suggests that MSM taking PrEP are more sexually satisfied, although the reasons for this are 
unclear and future research on this is needed.  
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 Similar to other UK based research about the acceptability of PrEP,22 but contrary to 
an international review,24 younger MSM (18-24 years) were less likely to be taking PrEP 
compared to older MSM. This could be due to a UK specific barriers for younger MSM and 
concerns about adherence,22 age related differences in sexual risk, or a difference between 
intention to take PrEP and actual PrEP use. Despite the possible difference between intention 
and behaviour, lower education attainment was associated with lower uptake of PrEP, and 
has previously been associated with lower intention to use PrEP.24,31 A possible method to 
overcome this would be to provide education to all MSM engaging with sexual health 
services about PrEP, and if their engagement with services is poor, then community outreach 
to raise awareness of PrEP may be needed to reach these MSM. There is a large difference 
between the proportion of MSM in previous research stating acceptability of PrEP use,24,31,32 
and the proportion of MSM using PrEP in this study, which could also reflect the gap 
between intention and behaviour.33 Alternatively, this could be a reflection of the limited 
number of spaces for the PrEP IMPACT trial in England and Wales, although MSM have 
been purchasing PrEP privately and through online pharmacies prior to this trial.6 
Interestingly, four MSM who reported taking PrEP did not report any CAI in the past 12 
months, which may be due to intention to have CAI in the future, or as an extra protective 
measure alongside condoms, as these MSM had engaged in anal intercourse. 
Both recent chemsex and sexualised drug use were associated with PrEP use at 
bivariate level, but only chemsex was associated with PrEP use in the multivariable analysis, 
probably due to chemsex being a higher risk component of sexualised drug use. This higher 
proportion of PrEP use among MSM engaging in chemsex has been observed among MSM in 
Amsterdam.20 When analysing drug and condom use, it was unsurprising that MSM on PrEP 
engaging in sex under the influence of alcohol or cannabis, or who had taken poppers or 
EDDs immediately before or during sex, were more likely to have CAI, as past CAI and 
 14 
 
intention to have CAI are criteria for access PrEP in England.6 Whilst higher proportions of 
MSM on PrEP using chemsex related drugs for sex had CAI (e.g. GHB/GBL, crystal 
methamphetamine and mephedrone), these findings were not significant, possibly due to the 
small numbers taking these drugs, or that a high proportion of MSM not on PrEP taking these 
drugs for sex also engage in CAI. Future research regarding PrEP and sexualised drug use is 
needed, to analyse whether engagement in sexualised drug use has an impact on adherence or 
drug effectiveness, especially for chemsex, due to the prolonged sexual activity and types of 
drugs used.15  
Whilst Facebook advertising and using community organisations’ social media 
accounts facilitated the large sample size and recruitment of MSM across the UK, it is 
important to acknowledge that recruitment was limited to MSM who engaged with social 
media. People of colour are under represents in this sample (compared to the general UK 
population) and the results will not fully reflect MSM who are people of colour. Low 
awareness and uptake of PrEP has been observed among Black MSM in the USA,34 however 
we were unable explore this, and future UK research should aim to investigate if a similar 
pattern exists. Information about actual PrEP usage, such as adherence, source, and previous 
or duration of usage, were not collected and so these could not be explored in this study. 
Furthermore, data on frequency of clinic attendance would provide more information 
regarding whether MSM are repeatedly adhering to guidelines. Due to the cross-sectional 
method used, this study relied on self-report measures. Although where possible standard 
tools and questions were used, responses may still be subject to recall bias.  
In conclusion, the present study has demonstrated that whilst MSM taking PrEP 
across the UK are more likely to engage in high risk sexual behaviours, they are also 
engaging with sexual health services. This not only has an impact on their own sexual health, 
but will help reduce STI transmission. There is a growing concern that PrEP might be 
 15 
 
contributing to the increase in STI diagnoses among MSM. However, for HIV-negative MSM 
consistently engaging in CAI, taking PrEP and increased engagement with sexual health 
services are currently the best available approaches to reducing HIV/STI transmission.  
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